Randomized contorol trial of transarterial chemoinfusion with cisplatin-lipiodol susupension or miriplatin-lipiodol suspension for advanced HCC
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000003452
- Lead Sponsor
- First Department of Internal Medicine,Gifu University Hospital
- Brief Summary
The 1-year survival rates in the cisplatin and miriplatin groups were 84.0% and 77.7%, and the 2-year survival rates were 60.0% and 51.8% respectively. (P = 0.905).The 1-year survival rates in the cisplatin and miriplatin groups with TAI alone were 71.4% and 71.4%, and the 2-year survival rates cannot be calculated yet. (P = 0.695).TE evaluation, the 1-year survival rates in TE3+4 and TE1+2 groups were 100% and 62.1%, and the 2-year survival rates were 66.7% and 33.1% respectively. (P = 0.0263).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 98
Not provided
1)Patienta with sever co-morbidity such as cardiac failure or renal failure 2)Patienta with a medical history of severe hypersensitivity 3)Patients who are pregnant,lactating or are suspected to be a pregnant 4)Patients who are concluded to be inappropriate to participate in this study by their physitians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method